en · de · es · fr · pt
bpc-157-notes.peptides9000.com › Data › Bpc-157 Identity And Origin — Explained

Bpc-157 Identity And Origin — Explained

By Editorial Desk · published 2026-04-14 · last reviewed 2026-05-31 · Data

Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.

BPC-157 Identity and Origin

Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.

Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.

BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.

Background, Origin, and Naming

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Bpc-157 at a glance

PropertyValueNotes
ClassSynthetic peptideLinear, fifteen residues
SequenceGEPPPGKPADDAGLVSingle-letter amino acid code
Approximate mass1419 DaValue reported for the free peptide
Reported originFragment of a gastric juice proteinUsed as the design template
Common synonymsBody protection compound 157; PL 14736Naming varies across papers and suppliers

Research Literature and Evidence Status

Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.

Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.

Related pages on this site

Handling, Storage, and Analytical Methods

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.

Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.

Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.

Background and Chemical Identity

Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Discovery and Research Background

Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.

Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.

BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.

Supporting material

Protein therapeutics possess advantages over small molecule approaches including high target specificity and low off target effects with normal biological processes. Human serum albumin (HSA) is one of the most abundant blood proteins. It serves as a transport protein for several endogenous and exogenous ligands as well as various drug molecules. HSA nanoparticles have long been the center of attention in the pharmaceutical industry due to their ability to bind to various drug molecules, high storage stability and in vivo application, non–toxicity and antigenicity, biodegradability, reproducibility, scale–up of the production process and a better control over release properties. In addition, significant amounts of drugs can be incorporated into the particle matrix because of the large number of drug binding sites on the albumin molecule. Therefore, the combination of HSA-NPs and GO-NSs could be useful for reducing the cytotoxicity of GO-NSs and the enhancement of drug loading and sustained drug release in cancer therapy.

=== Properties === Like other peptides belonging to the super-family of the ICK, GsMTx-4 is amphipathic. Therefore, GsMTx-4 is able to interact with the hydrophobic side of the lipid bilayer. It can insert itself into the membrane by binding to anionic and cationic groups based on hydrophobic and electrostatic interactions. However, GsMTx-4 has a weak selectivity for the anionic phospholipids over the zwitterionic phospholipids of the lipid bilayer compared to other ICK peptides. For all ICK blocker peptides, the dominating aromatic residues in the hydrophobic face are widely considered to promote the binding and adsorption of the peptide to the lipid bilayer by positively contributing to its bilayer partitioning energy. Compared with other ICK peptides, GsMTx-4 has a relatively high content of lysine residues, which causes the peptide to be more positively charged. This is important for its orientation and depth of the peptide penetration into the lipid bilayer.

During Mahathir's term, Mahathir maintained a collaborative relationship with the West, despite him being an outspoken critic and prioritised development models and collaboration from elsewhere in Asia. On his first day in office, Mahathir announced that his government would prioritise strengthening ties with neighbouring ASEAN countries, particularly through closer economic cooperation. He chose neighbouring Indonesia for his first official overseas visit. Early during his tenure, a small disagreement with the United Kingdom over university tuition fees led to a boycott of all British goods led by Mahathir, in what became known as the "Buy British Last" campaign. Mahathir successfully negotiated with Indonesian President Suharto to bring the 27-year Ligitan and Sipadan dispute with Indonesia to the International Court of Justice for resolution. In a shift from his predecessors, Mahathir frequently condemned Israel and ensured Malaysian support for the Palestine Liberation Organization, although he toned down his criticisms after the Oslo Accords were agreed. He has been internationally acclaimed as the voice of the developing world. As prime minister, Mahathir undertook numerous international visits to enhance diplomatic relations, promote trade, and gather insights on foreign nations. In 1987, he was elected as the president of the International Conference on Drug Abuse and Illicit Trafficking.

The stylised lily, or fleur-de-lis (lily flower) has long been associated with royalty, although it may originally have been derived from the form of an iris. It has also been associated with the head of a spear. Its three parts have been associated with the three classes of mediaeval society, or alternatively faith, wisdom and chivalry. Whatever its exact derivation, it has come to be associated with France and the French monarchy since the earliest Frankish kings. Consequently, it became incorporated into not only French heraldry but also into many heraldic devices in jurisdictions where there had been historic French influence, such as Quebec and New Orleans. In modern times it appears in many forms, symbolic and decorative, and can be used on compasses to indicate the direction north, as well as the Scouting movement.

Although Jaffe's name is synonymous with clinical creatinine testing, his paper only described the principle behind what would later become the enduring method. It was Otto Folin (1867–1934), a Harvard biochemist, who adapted Jaffe's research—abandoning the standard Neubauer reaction of the time—and published several papers using the Jaffe reaction to analyze creatinine levels in both blood and urine. Folin began using the picric acid procedure in 1901 and included it in his 1916 Lab Manual of Biological Chemistry. During his career, Folin modified and improved several quantitative colorimetric procedures, the first of which was for creatinine. He took advantage of technology available at the time, using a Duboscq colorimeter for measurement precision, and is credited for introducing colorimetry into modern biochemical analysis. Folin's research did not focus on creatinine as a renal function indicator. Since the precursors of creatinine are synthesized in the liver, at this point in history, creatinine was considered indicative of liver function. It was not until 1926 that Poul Kristian Brandt Rehberg suggested creatinine was a significant marker for renal function.

Sources: en.wikipedia.org

Supporting material

1993/616) Magistrates' Courts (Reciprocal Enforcement of Maintenance Orders) (Miscellaneous Amendments) Rules 1993 (S.I. 1993/617) Maintenance Orders (Reciprocal Enforcement) Act 1992 (Commencement) Order 1993 (S.I. 1993/618) Public Trustee (Fees) (Amendment) Order 1993 (S.I. 1993/619) Child Maintenance (Written Agreements) Order 1993 (S.I. 1993/620) Children (Admissibility of Hearsay Evidence) Order 1993 (S.I. 1993/621) High Court (Distribution of Business) Order 1993 (S.I. 1993/622) Maintenance Orders (Backdating) Order 1993 (S.I. 1993/623) Children (Allocation of Proceedings) (Amendment) Order 1993 (S.I. 1993/624) Education (Listed Bodies) Order 1993 (S.I. 1993/625) Education (Recognised Bodies) Order 1993 (S.I. 1993/626) Family Proceedings Courts (Child Support Act 1991) Rules 1993 (S.I. 1993/627) Education (Queen Elizabeth Atherstone Further Education Corporation) (Dissolution) Order 1993 (S.I. 1993/628) National Board for Nursing, Midwifery and Health Visiting for England (Constitution and Administration) Order 1993 (S.I. 1993/629) Motor Vehicles (Type Approval and Approval Marks) (Fees) Regulations 1993 (S.I. 1993/630) A65 Trunk Road (Hellifield and Long Preston Bypass and Slip Roads) Order 1993 (S.I. 1993/631) A65 Trunk Road (Bigholmes Lane to Switchers) (Detrunking) Order 1993 (S.I. 1993/632) National Board for Nursing, Midwifery and Health Visiting for Scotland Order 1993 (S.I. 1993/637) Lothian and Central Regions and West Lothian and Falkirk Districts (Mannerston/Cauldcoats Holdings and M9 Motorway) Boundaries Amendment Order 1993 (S.I.

Potassium alum is used in medicine mainly as an astringent (or styptic) and antiseptic. Styptic pencils are rods composed of potassium alum or aluminum sulfate, used topically to reduce bleeding in minor cuts (especially from shaving) and abrasions, nosebleeds, and hemorrhoids, and to relieve pain from stings and bites. Potassium alum blocks are rubbed over the wet skin after shaving. Potassium alum is also used topically to remove pimples and acne, and to cauterize aphthous ulcers in the mouth and canker sores, as it has a significant drying effect to the area and reduces the irritation felt at the site. It has been used to stop bleeding in cases of hemorrhagic cystitis and is used in some countries as a cure for hyperhidrosis. It is used in dentistry (especially in gingival retraction cords) because of its astringent and hemostatic properties. Potassium and ammonium alum are the active ingredients in some antiperspirants and deodorants, acting by inhibiting the growth of the bacteria responsible for body odor. Alum's antiperspirant and antibacterial properties contribute to its traditional use as an underarm deodorant. It has been used for this purpose in Europe, Mexico, Thailand (where it is called sarn-som), throughout Asia and in the Philippines (where it is called tawas). Today, potassium or ammonium alum is sold commercially for this purpose as a "deodorant crystal". Beginning in 2005 the US Food and Drug Administration no longer recognized it as a wetness reducer, but it is still available and used in several other countries, primarily in Asia.

Large subunit ribosomal ribonucleic acid (LSU rRNA) is the largest of the two major RNA components of the ribosome. Associated with a number of ribosomal proteins, the LSU rRNA forms the large subunit of the ribosome. The LSU rRNA acts as a ribozyme, catalyzing peptide bond formation.

==== Foreign policy ==== On June 12, 2017, U.S. senators agreed to legislation imposing new sanctions on Russia and Iran. The bill was opposed only by Sanders and Republican Rand Paul. He supported the sanctions on Russia, but voted against the bill because he believed the sanctions could endanger the Iran nuclear deal. In 2018, Sanders sponsored a bill and was joined by senators Chris Murphy (D–CT) and Mike Lee (R–UT) to invoke the 1973 War Powers Resolution to end US support for the Saudi-led military intervention in Yemen, which has resulted in hundreds of thousands of civilian casualties and "millions more suffering from starvation and disease". After the assassination of Jamal Khashoggi in October 2018 (which was ordered by Saudi Arabian crown prince Mohammad bin Salman, according to multiple intelligence agencies), his bill attracted bipartisan co-sponsors and support, and the Senate passed it by a vote of 56–41. The bill passed the House in February 2019 by a 247–175 vote and President Trump vetoed it in March, saying: "This resolution is an unnecessary, dangerous attempt to weaken my constitutional authorities, endangering the lives of American citizens and brave service members, both today and in the future." During the Gaza war, Sanders introduced several Joint Resolutions of Disapproval to block arms to Israel. All failed, but some Democrats voted for them. In November 2024, one such resolution garnered support from 18 senators. In April 2025, 15 senators supported another. In July 2025, 27 senators supported a resolution, a majority of Senate Democrats.

== Function == The SMN protein contains GEMIN2-binding, Tudor and YG-Box domains. It localizes to both the cytoplasm and the nucleus. Within the nucleus, the protein localizes to subnuclear bodies called gems which are found near coiled bodies containing high concentrations of small ribonucleoproteins (snRNPs). This protein forms heteromeric complexes with proteins such as GEMIN2 and GEMIN4, and also interacts with several proteins known to be involved in the biogenesis of snRNPs, such as hnRNP U protein and the small nucleolar RNA binding protein.

Sources: en.wikipedia.org

Notes from published material

Teratogenicity The teratogenic effects of aflatoxin B1 in rabbits have been reported to include reduced fetal weights, wrist drop, enlarged eye socket, agenesis of caudal vertebrae, micropthalmia, cardiac defects, and lenticular degeneration, among others. Immunotoxicity Studies in fish showed aflatoxin B1 to have significant immunosuppressive effects including reduced serum total globulin and reduced bactericidal activities.

The term "catatonia" was first used by German psychiatrist Karl Ludwig Kahlbaum in 1874, in his book Die Katatonie oder das Spannungsirresein, which translates to "Catatonia or Tension Insanity". He viewed catatonia as its own illness, which would get worse over time in stages of mania, depression, and psychosis leading to dementia. This work heavily influenced another German psychiatrist, Emil Kraeplin, who was the first to classify catatonia as a syndrome. Kraeplin associated catatonia with a psychotic disorder called dementia praecox, which is no longer used as a diagnosis, but heavily informed the development of the concept of schizophrenia. Kraeplin's work influenced two other notable German psychiatrists, Karl Leonhard and Max Fink, and their colleagues to expand the concept of catatonia as a syndrome which could occur in the setting of many mental illnesses, not just psychotic disorders. They also laid the groundwork to describe different subtypes of catatonia still used today, including Stuporous Catatonia, Excited Catatonia, Malignant Catatonia, and Periodic Catatonia. Additionally, Leonhard and his colleagues categorized catatonia as either systematic or unsystematic, based on whether or not symptoms happened according to consistent and predictable patterns. These ways of thinking shaped the way that psychologists and psychiatrists thought of catatonia well into the 20th century. In fact, catatonia was a subtype of schizophrenia as recently as the DSM-III, and was not revised to be able to be applied to mood disorders until 1994 with the release of the DSM-IV.

=== Constitutional reform === In 1988, new amendments to the Yugoslav Constitution were adopted, initiating a process of democratization. During 1988 and 1989, a successful round of coups in the Communist party leadership, known as the anti-bureaucratic revolution, in Vojvodina, Kosovo as well as Montenegro, replaced autonomous leaderships in this regions. The coups were led by Slobodan Milošević; supporter of Serbian nationalism. The events were condemned by the communist governments of the western Yugoslav republics (especially SR Slovenia and SR Croatia), who successfully resisted the attempts to expand the revolt onto their territories, and turned against Milošević. The rising antagonism eventually resulted in the dissolution of the ruling League of Communists of Yugoslavia in 1990, and subsequently in the breakup of Yugoslavia. In 1989, Slobodan Milošević was elected as President of the State Presidency of Serbia. He demanded that the federal Yugoslav government act for the interests of Serbia in Kosovo by sending in the Yugoslav People's Army to suppress separatism in the province. At the same time, several reforms of federal electoral system were proposed, with Serbia supporting a "one-citizen, one-vote" system, which would have given a majority of votes to Serbs. By that time, ethnic tensions in Yugoslavia increased, and the ruling League of Communists of Yugoslavia collapsed, followed by the crisis of federal institutions.

In another collaborative study published in Scientific Reports, he found that S-glutathionylated serpins, specifically A1 and A3, are elevated in the blood of prostate cancer patients after radiation therapy, suggesting their potential as biomarkers for radiation exposure. He also explored melanoma cell lines resistant to reductive stress agents, showcasing changes in cell and mitochondrial morphology, metabolic preferences, and adaptive mechanisms in lethal reductive stress conditions.

=== Legal status === As a result of the United Nations 1971 Convention on Psychotropic Substances, amphetamine became a schedule II controlled substance, as defined in the treaty, in all 183 state parties. Consequently, it is heavily regulated in most countries. Some countries, such as South Korea and Japan, have banned substituted amphetamines even for medical use. In other nations, such as Brazil (class A3), Canada (schedule I drug), the Netherlands (List I drug), the United States (schedule II drug), Australia (schedule 8), Thailand (category 1 narcotic), and United Kingdom (class B drug), amphetamine is in a restrictive national drug schedule that allows for its use as a medical treatment.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 chemically?

It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.

Does it occur naturally in the body?

The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.

Is it an approved drug?

No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.

What is BPC-157?

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.

Network